MYLK pathogenic variants aortic disease presentation, pregnancy risk, and characterization of pathogenic missense variants.


Journal

Genetics in medicine : official journal of the American College of Medical Genetics
ISSN: 1530-0366
Titre abrégé: Genet Med
Pays: United States
ID NLM: 9815831

Informations de publication

Date de publication:
01 2019
Historique:
received: 23 05 2017
accepted: 02 04 2018
pubmed: 22 6 2018
medline: 13 3 2019
entrez: 22 6 2018
Statut: ppublish

Résumé

Heritable thoracic aortic disease can result from null variants in MYLK, which encodes myosin light-chain kinase (MLCK). Data on which MYLK missense variants are pathogenic and information to guide aortic disease management are limited. Clinical data from 60 cases with MYLK pathogenic variants were analyzed (five null and two missense variants), and the effect of missense variants on kinase activity was assessed. Twenty-three individuals (39%) experienced an aortic event (defined as aneurysm repair or dissection); the majority of these events (87%) were aortic dissections. Aortic diameters were minimally enlarged at the time of dissection in many cases. Time-to-aortic-event curves showed that missense pathogenic variant (PV) carriers have earlier-onset aortic events than null PV carriers. An MYLK missense variant segregated with aortic disease over five generations but decreases MYLK kinase acitivity marginally. Functional Assays fail to identify all pathogenic variants in MYLK. These data further define the aortic phenotype associated with MYLK pathogenic variants. Given minimal aortic enlargement before dissection, an alternative approach to guide the timing of aortic repair is proposed based on the probability of a dissection at a given age.

Identifiants

pubmed: 29925964
doi: 10.1038/s41436-018-0038-0
pii: S1098-3600(21)00102-7
pmc: PMC6400320
mid: NIHMS956582
doi:

Substances chimiques

Calcium-Binding Proteins 0
MYLK protein, human EC 2.7.11.18
Myosin-Light-Chain Kinase EC 2.7.11.18

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

144-151

Subventions

Organisme : NHLBI NIH HHS
ID : P01 HL110869
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL062594
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL109942
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000371
Pays : United States

Références

Guo DC, Pannu H, Papke CL, et al. Mutations in smooth muscle alpha-actin (ACTA2) lead to thoracic aortic aneurysms and dissections. Nat Genet. 2007;39:1488–93
doi: 10.1038/ng.2007.6
Disabella E, Grasso M, Gambarin FI, et al. Risk of dissection in thoracic aneurysms associated with mutations of smooth muscle alpha-actin 2 (ACTA2). Heart. 2011;97:321–6
doi: 10.1136/hrt.2010.204388
Guo DC, Regalado E, Casteel DE, et al. Recurrent gain-of-function mutation in PRKG1 causes thoracic aortic aneurysms and acute aortic dissections. Am J Hum Genet. 2013;93:398–404
doi: 10.1016/j.ajhg.2013.06.019
Wang L, Guo DC, Cao J, et al. Mutations in myosin light chain kinase cause familial aortic dissections. Am J Hum Genet. 2010;87:701–7
doi: 10.1016/j.ajhg.2010.10.006
Pannu H, Tran-Fadulu V, Papke CL, et al. MYH11 mutations result in a distinct vascular pathology driven by insulin-like growth factor 1 and angiotensin II. Hum Mol Genet. 2007;16:3453–62
doi: 10.1093/hmg/ddm201
Gao N, Huang J, He W, et al. Signaling through myosin light chain kinase in smooth muscles. J Biol Chem. 2013;288:7596–605
doi: 10.1074/jbc.M112.427112
Luyckx I, Proost D, Hendriks JM, et al. Two novel MYLK nonsense mutations causing thoracic aortic aneurysms/dissections in patients without apparent family history. Clin Genet. 2017;92:444–6
doi: 10.1111/cge.13000
Hannuksela M, Stattin EL, Klar J, et al. A novel variant in MYLK causes thoracic aortic dissections: genotypic and phenotypic description. BMC Med Genet. 2016;17:61
doi: 10.1186/s12881-016-0326-y
Ziganshin BA, Bailey AE, Coons C, et al. Routine genetic testing for thoracic aortic aneurysm and dissection in a clinical setting. Ann Thorac Surg. 2015;100:1604–11
doi: 10.1016/j.athoracsur.2015.04.106
Silberstein M, Tzemach A, Dovgolevsky N, et al. Online system for faster multipoint linkage analysis via parallel execution on thousands of personal computers. Am J Hum Genet. 2006;78:922–35
doi: 10.1086/504158
Rylski B, Blanke P, Beyersdorf F, et al. How does the ascending aorta geometry change when it dissects? J Am Coll Cardiol. 2014;63:1311–9
doi: 10.1016/j.jacc.2013.12.028
Leistritz DF, Pepin MG, Schwarze U, et al. COL3A1 haploinsufficiency results in a variety of Ehlers–Danlos syndrome type IV with delayed onset of complications and longer life expectancy. Genet Med. 2011;13:717–22
doi: 10.1097/GIM.0b013e3182180c89
Jondeau G, Ropers J, Reglado E, et al. International registry of patients carrying TGFBR1 or TGFBR2 mutations: results of the MAC (Montalcino Aortic Consortium). Circ Cardiovasc Genet. 2016;9:548–58
doi: 10.1161/CIRCGENETICS.116.001485
National Comprehensive Cancer Network. NCCN Guidelines Version 2.2017: BRCA-Related Breast and/or Ovarian Syndrome, 2017
Wang T, Brown M, Kelly G, et al. Myosin light chain kinase (MYLK) coding polymorphisms modulate human lung endothelial cell barrier responses via altered tyrosine phosphorylation, spatial localization and lamellipodial protrusions. Puml Circ; E-pub ahead of print 26 February 2018.
Dudek SM, Chiang ET, Camp SM, et al. Abl tyrosine kinase phosphorylates nonmuscle myosin light chain kinase to regulate endothelial barrier function. Mol Biol Cell. 2010;21:4042–56
doi: 10.1091/mbc.e09-10-0876
Patel AY, Eagle KA, Vaishnava P. Acute type B aortic dissection: insights from the International Registry of Acute Aortic Dissection. Ann Cardiothorac Surg. 2014;3:368–74
pubmed: 25133099 pmcid: 4128929
Loeys BL, Schwarze U, Holm T, et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med. 2006;355:788–98
doi: 10.1056/NEJMoa055695
Narod S, Lynch H, Conway T, et al. Increasing incidence of breast cancer in family with BRCA1 mutation. Lancet. 1993;341:1101–2
doi: 10.1016/0140-6736(93)92468-9

Auteurs

Stephanie E Wallace (SE)

Department of Internal Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas, USA.

Ellen S Regalado (ES)

Department of Internal Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas, USA.

Limin Gong (L)

Department of Internal Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas, USA.

Alexandra L Janda (AL)

Department of Internal Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas, USA.

Dong-Chuan Guo (DC)

Department of Internal Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas, USA.

Claudio F Russo (CF)

Division of Cardiac Surgery, Niguarda Ca' Granda Metropolital Hospital, Milan, Italy.

Richard J Kulmacz (RJ)

Department of Internal Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas, USA.

Nadine Hanna (N)

Département de Génétique, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris, France.
Laboratory for Vascular Translational Science, INSERM U1148, Université Paris Diderot, Hôpital Bichat, Paris, France.
Centre de Référence Maladies Rares Syndrome de Marfan et Pathologies Apparentées, Service de Cardiologie, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris, France.

Guillaume Jondeau (G)

Laboratory for Vascular Translational Science, INSERM U1148, Université Paris Diderot, Hôpital Bichat, Paris, France.
Centre de Référence Maladies Rares Syndrome de Marfan et Pathologies Apparentées, Service de Cardiologie, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris, France.

Catherine Boileau (C)

Département de Génétique, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris, France.
Laboratory for Vascular Translational Science, INSERM U1148, Université Paris Diderot, Hôpital Bichat, Paris, France.
Centre de Référence Maladies Rares Syndrome de Marfan et Pathologies Apparentées, Service de Cardiologie, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris, France.

Pauline Arnaud (P)

Département de Génétique, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris, France.
Laboratory for Vascular Translational Science, INSERM U1148, Université Paris Diderot, Hôpital Bichat, Paris, France.
Centre de Référence Maladies Rares Syndrome de Marfan et Pathologies Apparentées, Service de Cardiologie, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris, France.

Kwanghyuk Lee (K)

Center for Statistical Genetics, Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.

Suzanne M Leal (SM)

Center for Statistical Genetics, Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.

Matias Hannuksela (M)

Department of Surgical and Perioperative Sciences, Umeå University, Umeå, Sweden.

Bo Carlberg (B)

Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.

Tami Johnston (T)

Department of Clinical Diagnostics, Ambry Genetics, Aliso Viejo, California, USA.

Christian Antolik (C)

Department of Clinical Diagnostics, Ambry Genetics, Aliso Viejo, California, USA.

Ellen M Hostetler (EM)

Department of Internal Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas, USA.

Roberto Colombo (R)

Center for the Study of Rare Hereditary Diseases, Niguarda Ca' Granda Metropolitan Hospital, Milan, Italy.
Institute of Clinical Biochemistry, Faculty of Medicine, Catholic University, IRCCS Policlinico "Agostino Gemelli", Rome, Italy.

Dianna M Milewicz (DM)

Department of Internal Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas, USA. Dianna.M.Milewicz@uth.tmc.edu.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH